# Jaguar Health, Inc. (JAGX) · Edgar & Edgarette company card

> Jaguar Health (JAGX) saw revenue fall 1.5% in FY2025 to $12 million, operating margin -399% against a -3.8% median for pharmaceutical preparations, equity -48.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1585608 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/JAGX) · [JSON](https://www.pops4.com/boards/company/JAGX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $12M |
| Revenue growth, 1 year | -1.5% |
| Revenue growth per year | 27.7% |
| Operating margin | -398.8% (prior year -263.8%) |
| Net margin | -469.1% |
| Operating cash flow | −$24M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $968,000 |
| Long-term debt | — |
| Total assets | $38M |
| Total equity | −$19M |
| Equity ÷ assets | -48.8% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -45.89 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -6.63 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -398.8% in FY2025; revenue is hard to predict: its 80% range is ±76%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $11.5M (FY2025). Experience: revenue down 1.5% on the year, up 27.7% a year over 4 years; operating margin -398.8%, down from -263.8%. Soundness: equity -48.8% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4.1M and $30.7M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $3.6M to $35.4M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -398.8% against a -3.8% median; growth -1.5% against 13.7%.

Range logged 2026-09-24, receipt ca3fbb3ab9ba31cd, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-04-01 ([filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526137948/0001193125-26-137948-index.htm))
- Item 3.01 Exchange listing notice or transfer: 3, latest 2026-05-04 ([filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526202614/0001193125-26-202614-index.htm))
- Item NT 10-Q Late quarterly report notice: 2, latest 2026-08-14 ([filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526352657/0001193125-26-352657-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526445055/0001193125-26-445055-index.htm)
- 8-K · filed 2026-10-28 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526436334/0001193125-26-436334-index.htm)
- DEF 14A · filed 2026-10-08 · [filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526417938/0001193125-26-417938-index.htm)
- 8-K · filed 2026-10-05 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526413233/0001193125-26-413233-index.htm)
- 8-K · filed 2026-09-28 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526403356/0001193125-26-403356-index.htm)
- 8-K · filed 2026-09-25 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1585608/000119312526401239/0001193125-26-401239-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001585608.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1585608

## Cite

POPS4, Edgar & Edgarette: Jaguar Health, Inc. (JAGX) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/JAGX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.